DK1480962T3 - 5-Phenylthiazol-derivater og deres anvendelse som P1-3-kinaseinhibitorer - Google Patents

5-Phenylthiazol-derivater og deres anvendelse som P1-3-kinaseinhibitorer

Info

Publication number
DK1480962T3
DK1480962T3 DK03709730.0T DK03709730T DK1480962T3 DK 1480962 T3 DK1480962 T3 DK 1480962T3 DK 03709730 T DK03709730 T DK 03709730T DK 1480962 T3 DK1480962 T3 DK 1480962T3
Authority
DK
Denmark
Prior art keywords
kinase inhibitors
phenylthiazole derivatives
phenylthiazole
derivatives
kinase
Prior art date
Application number
DK03709730.0T
Other languages
English (en)
Inventor
Ian Bruce
Peter Finan
Catherine Leblanc
Clive Mccarthy
Graham Charles Bloomfield
Judy Hayler
Mrinalini Sachin Oza
Lewis Whitehead
Nicola Elaine Press
Louise Kirman
Lena Shukla
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27767104&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1480962(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0204765A external-priority patent/GB0204765D0/en
Priority claimed from GB0229626A external-priority patent/GB0229626D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1480962T3 publication Critical patent/DK1480962T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
DK03709730.0T 2002-02-28 2003-02-27 5-Phenylthiazol-derivater og deres anvendelse som P1-3-kinaseinhibitorer DK1480962T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0204765A GB0204765D0 (en) 2002-02-28 2002-02-28 Organic compounds
GB0229626A GB0229626D0 (en) 2002-12-19 2002-12-19 Organic compounds
PCT/EP2003/002036 WO2003072557A1 (en) 2002-02-28 2003-02-27 5-phenylthiazole derivatives and use as pi3 kinase inhibitors

Publications (1)

Publication Number Publication Date
DK1480962T3 true DK1480962T3 (da) 2011-12-05

Family

ID=27767104

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10174528.9T DK2311818T3 (da) 2002-02-28 2003-02-27 Kombination af en 5-phenylthiazolforbindelse som PI3-kinasehæmmer med et antiinflammatorisk, bronchodilatorisk eller antihistaminisk medikament
DK03709730.0T DK1480962T3 (da) 2002-02-28 2003-02-27 5-Phenylthiazol-derivater og deres anvendelse som P1-3-kinaseinhibitorer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10174528.9T DK2311818T3 (da) 2002-02-28 2003-02-27 Kombination af en 5-phenylthiazolforbindelse som PI3-kinasehæmmer med et antiinflammatorisk, bronchodilatorisk eller antihistaminisk medikament

Country Status (27)

Country Link
US (2) US7687637B2 (da)
EP (1) EP1480962B1 (da)
JP (2) JP4408701B2 (da)
KR (1) KR100688370B1 (da)
CN (1) CN100548996C (da)
AR (1) AR038703A1 (da)
AT (1) ATE521598T1 (da)
AU (1) AU2003214080A1 (da)
BR (1) BR0308030A (da)
CA (1) CA2477601C (da)
CO (1) CO5611131A2 (da)
CY (2) CY1112084T1 (da)
DK (2) DK2311818T3 (da)
EC (2) ECSP045253A (da)
ES (2) ES2372597T3 (da)
IL (2) IL163691A0 (da)
MX (1) MXPA04008362A (da)
MY (1) MY156407A (da)
NO (1) NO329175B1 (da)
NZ (1) NZ534657A (da)
PE (1) PE20030968A1 (da)
PL (2) PL219449B1 (da)
PT (2) PT2311818E (da)
RU (2) RU2378263C2 (da)
SI (1) SI1480962T1 (da)
TW (1) TWI314928B (da)
WO (1) WO2003072557A1 (da)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523166A (ja) 1998-09-29 2003-08-05 ガミダ セル リミテッド 幹細胞および前駆細胞の増殖と分化を制御する方法
IL152904A0 (en) 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
EP1465982A4 (en) 2002-01-25 2006-06-07 Gamida Cell Ltd PROCESS FOR EXPANSION OF STEM AND PRESERVATIVE CELLS AND EXPANDED CELL POPULATIONS THEREWITH OBTAINED
US7265138B2 (en) 2003-02-10 2007-09-04 Amgen Inc. Vanilloid receptor ligands and their use in treatments
GB0305152D0 (en) 2003-03-06 2003-04-09 Novartis Ag Organic compounds
JP4758337B2 (ja) * 2003-03-31 2011-08-24 株式会社アールテック・ウエノ 血管透過性亢進疾患を治療する方法
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0320197D0 (en) 2003-08-28 2003-10-01 Novartis Ag Organic compounds
DE602005001931T2 (de) 2004-01-12 2008-04-24 Applied Research Systems Ars Holding N.V. Thiazolderivate und deren verwendung
KR101280095B1 (ko) 2004-08-28 2013-09-09 아스트라제네카 아베 케모킨 수용체 조절제로서의 피리미딘 술폰아미드 유도체
UY29149A1 (es) * 2004-10-07 2006-05-31 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles
KR20070064660A (ko) 2004-10-07 2007-06-21 베링거 인겔하임 인터내셔날 게엠베하 Ｐｉ３ 키나제
SE0402735D0 (sv) * 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
BRPI0610368A8 (pt) * 2005-05-05 2015-09-08 Glaxosmithkline Ip Dev Ltd Modulação de enzima e de receptor
DK1885716T3 (da) 2005-05-24 2013-02-11 Merck Serono Sa Thiazolderivater og anvendelse deraf
CA2607385C (en) * 2005-05-24 2014-12-16 Laboratoires Serono S.A. Thiazole derivatives and their use for the treatment and/or prophylaxis of disorders and diseases
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
US8105581B2 (en) * 2005-12-01 2012-01-31 The Scripps Research Institute Compositions and methods for inducing neuronal differentiation
GB0525671D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
EP1991528A2 (en) * 2006-01-18 2008-11-19 Siena Biotech S.p.A. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
MY149143A (en) * 2006-01-18 2013-07-15 Amgen Inc Thiazole compounds as protien kinase b (pkb) inhibitors
AU2007206860A1 (en) * 2006-01-23 2007-07-26 Laboratoires Serono S.A. Thiazole derivatives and use thereof
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
US7517995B2 (en) 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
US20070238746A1 (en) * 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
EP2016075A1 (en) * 2006-05-03 2009-01-21 AstraZeneca AB Thiazole derivatives and their use as anti-tumour agents
GB0608823D0 (en) * 2006-05-04 2006-06-14 Chroma Therapeutics Ltd Inhibitors of P13 kinase
GB0608854D0 (en) * 2006-05-04 2006-06-14 Chroma Therapeutics Ltd P13 kinase inhibitors
GB0610243D0 (en) 2006-05-23 2006-07-05 Novartis Ag Organic compounds
GB0612630D0 (en) * 2006-06-26 2006-08-02 Novartis Ag Organic compounds
US7589212B2 (en) * 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
RU2435763C2 (ru) * 2006-06-27 2011-12-10 Дзе Проктер Энд Гэмбл Компани Ингибиторы тирозинфосфатазы белка человека и способы применения
ATE414281T1 (de) 2006-08-03 2008-11-15 Cellzome Ag Verfahren zur identifizierung von molekülen die mit pi3k interagieren und verfahren zur reinigung von pi3k
CN101528738A (zh) * 2006-09-01 2009-09-09 沃泰克斯药物股份有限公司 可用作磷脂酰肌醇3-激酶抑制剂的5-（2-呋喃基）-1，3-噻唑衍生物
SG177144A1 (en) * 2006-11-29 2012-01-30 Abbott Lab Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
AU2008287542C1 (en) 2007-06-01 2015-01-22 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
AU2008276512A1 (en) * 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of PKB
US7897619B2 (en) 2007-07-17 2011-03-01 Amgen Inc. Heterocyclic modulators of PKB
EP2240475B1 (en) 2007-12-20 2013-09-25 Novartis AG Thiazole derivatives used as pi 3 kinase inhibitors
US20110111972A1 (en) 2008-02-04 2011-05-12 Cellzome Ag Selectivity profiling of pi3k interacting molecules against multiple targets
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
CN101684106B (zh) * 2008-09-22 2013-06-12 北京摩力克科技有限公司 噻唑鎓盐类化合物及其治疗蛋白老化相关疾病的用途
WO2010098428A1 (ja) * 2009-02-27 2010-09-02 帝人ファーマ株式会社 遷移金属触媒を用いたカップリング法によるフェニル置換複素環誘導体の製造法
TW201103943A (en) * 2009-04-27 2011-02-01 Shionogi & Co Urea derivative having pi3k inhibitory activity
MX2012000178A (es) 2009-07-02 2012-02-28 Novartis Ag 2-carboxamida-cicloamino-ureas utiles como inhibidores de pi3k.
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011048936A1 (ja) 2009-10-19 2011-04-28 大正製薬株式会社 アミノチアゾール誘導体
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
EP2531194B1 (en) 2010-02-03 2018-04-18 Signal Pharmaceuticals, LLC Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
WO2012071480A2 (en) * 2010-11-24 2012-05-31 Lithera, Inc. Lipophilic glucocorticosteroid monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
CA2843887A1 (en) 2011-08-03 2013-02-07 Signal Pharmaceuticals, Llc Identification of gene expression profile as a predictive biomarker for lkb1 status
US9926309B2 (en) 2011-10-05 2018-03-27 The Board Of Trustees Of The Leland Stanford Junior University Pi-kinase inhibitors with anti-infective activity
US9309236B2 (en) 2011-10-05 2016-04-12 The Board Of Trustees Of The Leland Stanford Junior University PI-kinase inhibitors with broad spectrum anti-infective activity
HK1202581A1 (en) 2012-02-13 2015-10-02 Gamida-Cell Ltd. Mesenchymal stem cells conditioned medium and methods of generating and using the same
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
US9937169B2 (en) 2013-04-17 2018-04-10 Signal Pharmaceuticals, Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
AU2014254052B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
TW201527300A (zh) 2013-04-17 2015-07-16 Signal Pharm Llc 關於１－乙基－７－（２－甲基－６－（１Ｈ－１，２，４－三唑－３－基）吡啶－３－基）－３，４－二氫吡并［２，３－ｂ］吡－２（１Ｈ）－酮之醫藥調配物、方法、固態型式及使用方法
BR112015026292B1 (pt) 2013-04-17 2022-04-12 Signal Pharmaceuticals, Llc Uso de 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino [2,3-b]pirazin-2(1h)- ona e métodos in vitro
TW201521725A (zh) 2013-04-17 2015-06-16 Signal Pharm Llc 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
US9782427B2 (en) 2013-04-17 2017-10-10 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
BR112015026297B1 (pt) 2013-04-17 2022-08-23 Signal Pharmaceuticals, Llc Uso de um inibidor da quinase tor e quinazolinona 5-substituída, composição farmacêutica que os compreende, e kit
EP3003313A1 (en) 2013-05-29 2016-04-13 Signal Pharmaceuticals, LLC Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
CN104418858B (zh) 2013-08-30 2018-12-11 浙江医药股份有限公司新昌制药厂 2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用
DE102013226711A1 (de) * 2013-12-19 2015-06-25 Beiersdorf Ag Verwendung von Alkylamidothiazolen in kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe vor und Behandlung von sensibler Haut
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015162584A1 (en) 2014-04-24 2015-10-29 Novartis Ag Crystalline forms of the sulfate salt of n-[5-(3-imidazol-1-yl-4-methanesulfonyl-phenyl)-4-methyl-thiazol-2-yl]-acetamide
WO2016065583A1 (en) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Oxazole orexin receptor antagonists
BR112018003622B8 (pt) * 2015-09-04 2022-08-23 Dow Agrosciences Llc Moléculas apresentando utilidade pesticida, e composição pesticida
AU2016317579B2 (en) * 2015-09-04 2018-10-04 Corteva Agriscience Llc Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
AU2016318336B2 (en) * 2015-09-10 2018-09-27 Corteva Agriscience Llc Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
DK3395801T3 (da) * 2015-12-16 2021-05-10 Nippon Soda Co Arylazolforbindelse og skadedyrsbekæmpelsesmiddel
WO2017132746A1 (en) 2016-02-01 2017-08-10 The Governing Council Of The University Of Toronto 53bp1 inhibitors
WO2017147526A1 (en) * 2016-02-26 2017-08-31 The Board Of Trustees Of The Leland Stanford Junior University Pi-kinase inhibitors with anti-infective activity
EP3641772B1 (en) 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
EP3713963A1 (en) * 2017-11-23 2020-09-30 INSERM (Institut National de la Santé et de la Recherche Médicale) A new marker for predicting the sensitivity to pi3k inhibitors
KR20220035322A (ko) * 2019-03-21 2022-03-22 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Pi4-키나아제 억제제 및 이의 사용 방법
PE20220346A1 (es) * 2019-08-28 2022-03-14 Novartis Ag Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades
CN115028596B (zh) * 2021-03-03 2024-06-07 帕潘纳(北京)科技有限公司 制备苯唑草酮中间体的方法
KR20250153183A (ko) 2022-12-19 2025-10-24 카마우 테라퓨틱스, 인크. P53 결합 단백질인 53bp1의 개선된 펩타이드 저해제
CN117384100A (zh) * 2023-10-13 2024-01-12 河南农业大学 一种多菌灵半抗原、人工抗原及其制备方法和应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB951885A (en) 1961-05-13 1964-03-11 Sankyo Co A new process for the preparation of thiazole compounds
OA01933A (fr) 1965-04-06 1970-02-04 Pechiney Saint Gobain Dérivés du thiazole.
US3749775A (en) 1969-07-07 1973-07-31 Stauffer Chemical Co Insecticidal 2-aminothiazole phosphates and phosphonates
FR2429210A1 (fr) 1978-06-19 1980-01-18 Fabre Sa Pierre Derives de phenyl-4 thiazolyl-2 oxamates utiles dans le traitement de l'asthme
DE3264595D1 (en) 1981-01-08 1985-08-14 Mitsui Toatsu Chemicals N-(4-phenyl-2-thiazolyl)carbamate derivatives, process for their preparation, and medicinal composition containing same
JPS57136579A (en) 1981-01-21 1982-08-23 Mitsui Toatsu Chem Inc Thiazolylurea derivative, its preparation, and pharmaceutical composition containing the same
DE3413755A1 (de) 1984-04-12 1985-10-24 Basf Ag, 6700 Ludwigshafen Thiazolylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
JPH0725754B2 (ja) 1986-01-30 1995-03-22 富山化学工業株式会社 新規なチアゾール化合物またはその塩
DE3864248D1 (de) 1987-12-14 1991-09-19 Sawai Seiyaku Kk Carboxamide mit tetrazol- und thiazol-ringen und ihre anwendung.
US4891375A (en) 1988-01-13 1990-01-02 Pfizer Inc. Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds
DK0934937T3 (da) 1990-11-30 2002-04-02 Otsuka Pharma Co Ltd Azolderivater som superoxidradikalinhibitor
DE4401911A1 (de) 1994-01-24 1995-08-03 Basf Ag Verwendung von Aryl- oder Heteroarylazoanilinen in der nichtlinearen Optik
EP0772606A1 (en) 1994-07-27 1997-05-14 G.D. SEARLE & CO. Substituted thiazoles for the treatment of inflammation
AU689972B2 (en) * 1994-11-29 1998-04-09 Hisamitsu Pharmaceutical Co., Inc. Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof
GB9625843D0 (en) * 1996-12-12 1997-01-29 Merck & Co Inc Phenyl spiroethercycloalkyl tachykinn receptor antagonists
SK286213B6 (sk) 1997-12-22 2008-05-06 Bayer Corporation Substituované heterocyklické močoviny, farmaceutický prípravok ich obsahujúci a ich použitie
EP0928790B1 (en) 1998-01-02 2003-03-05 F. Hoffmann-La Roche Ag Thiazole derivatives
US6100282A (en) * 1998-01-02 2000-08-08 Hoffman-La Roche Inc. Thiazole derivatives
US6043254A (en) 1998-04-03 2000-03-28 Boehringer Ingelheim Pharma Kg Indolinones having kinase-inhibiting activity
GB9823873D0 (en) * 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
EP1857443B1 (en) 2000-01-24 2012-03-28 AstraZeneca AB Therapeutic morpholino-substituted compounds
ES2788383T3 (es) 2000-04-25 2020-10-21 Icos Corp Inhibidores de delta fosfatidilo-inositol 3-quinasa humana
PL365170A1 (en) 2000-07-26 2004-12-27 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases
KR20090090406A (ko) 2000-12-18 2009-08-25 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 염증성 사이토카인 생산 유리 억제제
AR039059A1 (es) 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
US20040242637A1 (en) * 2001-08-17 2004-12-02 Hartman George D Tyrosine kinase inhibitors
US6812653B2 (en) * 2002-07-26 2004-11-02 Richard S. Bellivean Method and apparatus for controlling images with image projection lighting devices
GB0525671D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
JP2005522458A (ja) 2005-07-28
DK2311818T3 (da) 2013-05-06
AR038703A1 (es) 2005-01-26
ATE521598T1 (de) 2011-09-15
HK1071363A1 (en) 2005-07-15
PL370575A1 (en) 2005-05-30
RU2009132712A (ru) 2011-03-10
MXPA04008362A (es) 2004-11-26
PL403456A1 (pl) 2013-05-27
KR100688370B1 (ko) 2007-03-02
TWI314928B (en) 2009-09-21
CO5611131A2 (es) 2006-02-28
US8129541B2 (en) 2012-03-06
JP4408701B2 (ja) 2010-02-03
CY1112084T1 (el) 2015-11-04
PT2311818E (pt) 2013-05-15
CN1639139A (zh) 2005-07-13
KR20040091674A (ko) 2004-10-28
US20050119320A1 (en) 2005-06-02
NZ534657A (en) 2007-05-31
PE20030968A1 (es) 2004-01-12
PL219449B1 (pl) 2015-04-30
WO2003072557A1 (en) 2003-09-04
TW200303750A (en) 2003-09-16
RU2378263C2 (ru) 2010-01-10
NO329175B1 (no) 2010-09-06
IL163691A0 (en) 2005-12-18
PL215581B1 (pl) 2013-12-31
RU2004129279A (ru) 2005-06-27
ES2405816T3 (es) 2013-06-03
AU2003214080A1 (en) 2003-09-09
EP1480962A1 (en) 2004-12-01
JP2009298799A (ja) 2009-12-24
ES2372597T3 (es) 2012-01-24
EP1480962B1 (en) 2011-08-24
BR0308030A (pt) 2004-12-28
CA2477601A1 (en) 2003-09-04
MY156407A (en) 2016-02-26
ECSP105253A (es) 2010-09-30
NO20044095L (no) 2004-11-02
PT1480962E (pt) 2011-12-15
IL163691A (en) 2010-11-30
RU2436780C2 (ru) 2011-12-20
US20100093690A1 (en) 2010-04-15
ECSP045253A (es) 2004-09-28
CN100548996C (zh) 2009-10-14
CA2477601C (en) 2011-05-24
CY1114083T1 (el) 2016-07-27
US7687637B2 (en) 2010-03-30
SI1480962T1 (sl) 2011-12-30

Similar Documents

Publication Publication Date Title
DK1480962T3 (da) 5-Phenylthiazol-derivater og deres anvendelse som P1-3-kinaseinhibitorer
NO20053356L (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
NO20026010L (no) Substituerte quinazolinderivater og deres anvendelse som inhibitorer
DK1499311T3 (da) Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer
NO20030958D0 (no) Pyrazolderivater og deres anvendelse som proteinkinase inhibitorer
DK1478629T3 (da) N-aryl-2-oxazolidinon-5-carboxamider og deres derivater og deres anvendelse som antibakterielle midler
DK1480955T3 (da) O-cyclopropyl-carboxanilider og deres anvendelse som fungicider
DK1527050T3 (da) Quinolin-derivater og deres anvendelse som mycobakterielle inhibitorer
DK1648426T3 (da) Benzimidazolderivater og anvendelse heraf som proteinkinaseinhibitorer
NO20034324D0 (no) Bipiperidinylderivater og deres anvendelse som kjemokin reseptorinhibitor
DK1585749T3 (da) Diazepinoindol-derivater som kinaseinhibitorer
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
DK1956004T3 (da) Quinolinderivater og deres anvendelse som 5-HT6-ligander
ATE505471T1 (de) Azaindol-kinaseinhibitoren
DK1581532T3 (da) Pyrazolo-3,4-B pyridinforbindelser og deres anvendelse som phosphodiesterase inhibitorer
NO20042719L (no) Substituerte 2-amino-cykloalkankarboksamider og deres anvendelse som protease-inhibitorer
DK1539712T3 (da) Pyrimidinderivater og deres anvendelse som CB2-modulatorer
NO20032830D0 (no) Tetrahydropyridinderivater, fremstilling derav og anvendelse som celle-proliferasjonsinhibitorer
DK1636228T3 (da) Nye pyridopyraziner og deres anvendelse som kinasemodulatorer
DK1581518T3 (da) Substituerede 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazin-derivater og deres anvendelse som neurokinin antagonister
NO20043580D0 (no) Quinazolinonderivater og deres bruk som CB agonister
DK1387838T3 (da) Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
NO20034434D0 (no) Indolinoner substituert i 6-stilling og deres anvendelse som kinase-inhibitorer
DK1663982T3 (da) Aminoquinolinderivater og deres anvendelse som adenosin-A3-ligander
DK1709018T3 (da) Acylaminothiazolderivater og anvendelse deraf som beta-amyloid-hæmmere